Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Triggering receptor expressed in myeloid cells-1 (TREM1) is an important regulator of innate and adaptive immunity, which can directly amplify an inflammatory response. Current studies have found the immunomodulatory role of TREM1 in tumor microenvironment. However, the role of TREM1 in ovarian cancer (OV) remains unclear. Based on TCGA and GEO database, we performed bioinformatics analysis to evaluate the expression profile of TREM1. Then, the prognostic value of TREM1 was determined through Kaplan-Meier survival analyses. GO and KEGG enrichment along with GSEA analyses were performed to identify potential biological functions of TREM1 based on the gene co-expression network. IHC and RT-qPCR on clinical samples were performed to validate our database-derived results. Additionally, ESTIMATE and CIBERSORT analyses were used to assess the correlation between TREM1 and tumor microenvironment. Finally, the expression, prognosis and immune regulation patterns of TREM1 in pan-cancer were further explored to validate the role of TREM1 as a biomarker. The expression of TREM1 is abnormally high in OV than in normal tissues. Patients with high TREM1 expression were linked with poor overall survival (OS) and disease-free survival (DFS). Then, cox regression analysis and a nomogram indicated that TREM1 was an independent prognostic factor and proved the effective predictive performance in OV. Enrichment analysis showed that TREM1 was highly enriched in cancer-and immune-related pathways. Additionally, immune analysis revealed that TREM1 was robustly positively associated with tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) infiltrating. Moreover, pan-cancer analysis showed TREM1 was closely associated with prognosis and immune-related genes expression in various types of cancer. Through a systematic and comprehensive analysis, our study revealed that TREM1 could serve as a prognostic and immunological biomarker in ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685700 | PMC |
| http://dx.doi.org/10.7150/jca.101152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Jiuwei Zhenxin granules on serum TREM1 expression and its regulatory role in depression and anxiety in patients with coronary heart disease.
Medicine (Baltimore)
September 2025
Pediatric Laboratory, Hunan Provincial People's Hospital (The First Hospital Affiliated with Hunan Normal University) Laboratory Physician, Changsha, China.
This study explored the effects of Jiuwei Zhenxin (JWZX) granules on serum triggering receptor expressed on myeloid cells 1 (TREM1) levels and their role in regulating depression and anxiety in patients with coronary heart disease (CHD). A total of 100 CHD patients were enrolled from January 2020 to January 2023: 50 received JWZX granules and 50 underwent conventional treatment. Clinical data and psychological scores were collected.
View Article and Find Full Text PDFTREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma.
Mol Ther Oncol
September 2025
Christine Kühne - Center for Allergy Research and Education, 7265 Davos, Switzerland.
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is highly aggressive with limited curative options, primarily surgical resection. However, only about 20% of the tumors are resectable at diagnosis. Immunotherapies have largely failed in PDAC due to its immunosuppressive tumor microenvironment (TME).
View Article and Find Full Text PDFTriggering receptor expressed on myeloid cells 2 (TREM2) dysfunction contributes to Alzheimer's disease pathogenesis, yet current therapeutics cannot prevent ADAM-mediated receptor shedding that diminishes signaling efficacy. Using Affinity Selection-Mass Spectrometry (AS-MS) screening, we identified As48, a novel small molecule that binds TREM2 with high affinity. Biophysical validation confirmed s 7-fold selectivity over TREM1.
View Article and Find Full Text PDFBackground: Triggering receptor expressed on myeloid cells 1 (TREM-1), an inflammation amplifier, is an emerging target in inflammation and oncology.
Objective: To test my hypothesis that pan-TREM-1 and macrophage-restricted TREM-1 blockades may differ in their efficacy in cancer and other inflammatory diseases.
Methods: Ligand-independent TREM-1 inhibitory peptides GF9 and GA31 (the latter in a form of macrophage-targeted lipopeptide complexes, GA31-LPC) were used as pan-TREM-1 and macrophage-restricted TREM-1 inhibitors, respectively, to test the hypothesis in multiple animal models of cancer, sepsis, pulmonary inflammation and fibrosis.
DNA methylation regulates TREM1 expression to modulate immune responses and drive progression in colorectal neuroendocrine neoplasm as a potential therapeutic target.
Discov Oncol
August 2025
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Background: Colorectal neuroendocrine neoplasms (CrNENs) are rare malignancies with limited therapeutic options and poorly understood molecular mechanisms. The roles of genetic, epigenetic, and immune factors in CrNEN progression remain largely unknown.
Methods: We employed an integrative multi-omics approach combining two-sample Mendelian randomization, Bayesian colocalization, methylation quantitative trait loci (mQTLs), cis-expression QTLs (cis-eQTLs), protein QTLs (pQTLs), summary data-based Mendelian randomization, mediation analyses, immunohistochemistry validation, and pan-cancer validation using TCGA and GTEx data, including DNA methylation profiling using the SMART, UALCAN, UCSC Xena and MethSurv platforms to provide integrative insights into potential epigenetic regulation in oncogenesis.